Hematology 2021: Nonmalignant

CME

Key Studies in Nonmalignant Hematology: Independent Conference Coverage of ASH 2021

Physicians: Maximum of 1.25 AMA PRA Category 1 Credits

Released: March 01, 2022

Expiration: February 28, 2023

David Dingli
David Dingli, MD, PhD
Mark A. Schroeder
Mark A. Schroeder, MD
Sujit Sheth
Sujit Sheth, MD

Activity

Progress
1
Course Completed
Key Studies in Nonmalignant Hematology

At the 2021 American Society of Hematology (ASH) Annual Meeting, new clinical trial data in nonmalignant hematologic disorders were reported, including novel therapies for acute or chronic graft-vs-host disease (GVHD), hereditary blood disorders (hemophilia and sickle cell disease SCD), and acquired blood diseases (paroxysmal nocturnal hemoglobinuria PNH).

In this module, David Dingli, MD, PhD; Mark A. Schroeder, MD; and Sujit Sheth, MD, review and discuss the clinical implications of key studies in these hematologic disorders that were presented at the annual ASH meeting.

Please note that the slide thumbnails in this activity link to brief PowerPoint slidesets that can also be found here, each focused on the specific study or topic of interest. These slidesets also may be downloaded by clicking on any of the thumbnails within the activity.

Clinical Care Options plans to measure the educational impact of this activity. A few questions will be asked twice: Once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a practicing healthcare professional, how many patients with nonmalignant hematologic disorders do you provide care for in a typical month?

Pratta and colleagues reported data from 2 prospective trials evaluating longitudinal plasma samples in patients with acute GVHD (aGVHD) to investigate biomarkers predictive of survival identified in the UMN study cohort and validated in REACH1 study cohort. According to that report, high levels of which biomarker(s) was significantly associated with rapid fatal outcome in both cohorts and could potentially be assessed in patients being treated with ruxolitinib?

Which patient population with hemophilia has an unmet need and could benefit the most from fitusiran treatment?

At the annual ASH meeting, Heeney and colleagues reported results from the phase II SOLACE-kids trial of crizanlizumab, a first-in-class humanized monoclonal antibody that binds to P-selectin. The study is designed to establish optimal dosing and confirm safety for crizanlizumab in children so to expand treatment options for pediatric patients with SCD. All of these results were reported for that study EXCEPT which one?

You recently attended the 2021 ASH annual meeting, and a colleague caring for patients with PNH asks you to share insight from the ongoing phase II study of iptacopan in adult Asian patients with active PNH, anemia, and active clone size ≥10%. Which of the following results will you mention was reported from that trial?